BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target

BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Avalo Therapeutics (NASDAQ: AVTX) and maintained a price target of $40 for the stock. This endorsement suggests confidence in the company's future performance.